Conference Presentations

2015

  • Improved diagnosis of tumor tissues with QUESPOWR MRIRandtke EA, Pagel MD, Cárdenas-Rodríguez J. Proc ISMRM, Toronto, ON, Canada, #1757, 6/2/15.
  • Optimization of pulsed CEST imaging using genetic algorithm.  Yoshimaru E, Randtke EA, Pagel MD, Cárdenas-Rodríguez J. Proc ISMRM, Toronto, ON, Canada, #4680, 6/4/15.
  • A robust method to estimate CEST MRI parametric maps in vivo: Simultaneous quantification of concentration and exchange rate by minimizing the Lp norm.  Cárdenas-Rodríguez J, Pagel MD. Proc ISMRM, Toronto, ON, Canada, #3343, 6/1/15.
  • Quantum Chemical Prediction and Experimental Validation of the Characteristics of DiaCEST MRI Contrast Agents. Montano LA, Randtke EA, Jones KM, Pagel MD, Cárdenas-Rodríguez J. Proc ISMRM, Toronto, ON, Canada, #1758, 6/4/15.

2014

  • Monitoring early therapeutic response by measuring extracellular pH in a tumor model with acidoCEST MRI.  Akhenblit PJ, Howison CM, Malm SW, Chen  LQ, Baker AF, Pagel MD. American Association for Cancer Research, San Diego CA, 4/8/14.
  • Evaluation of pH in a lung fibrosis mouse model using respiration gated acidoCEST MRI.  Jones KM, Randtke EA, Howison CM, Kottman M, Sime P, Pagel MD. CEST Workshop, Milan Italy, 5/8/14.
  • A comparison of iopromide and iopamidol, two acidoCEST MRI contrast agents that measure tumor extracellular pH.  Moon BF, Chen LQ, Liu P, Howison CM, Jones KM, Pagel MD. CEST Workshop, Milan Italy, 5/8/14
  • Monitoring early therapeutic response by measuring extracellular pH in a tumor model with acidoCEST MRI. Akhenblit PJ, Howison CM, Malm SW, Chen  LQ, Baker AF, Pagel MD. CEST Workshop, Milan Italy, 5/8/14.
  • Clinical implementation of the Linear Reference Region Model for Dynamic Contrast-Enhanced MRI.  Bernstein A, Kuo PH, Pagel MD, Cardenas-Rodriguez J.  Proc ISMRM, Milan Italy, #2750, 5/13/14.
  • A comparison of iopromide and iopamidol, two acidoCEST MRI contrast agents that measure tumor extracellular pH.  Moon BF, Chen LQ, Liu P, Howison CM, Jones KM, Pagel MD. Proc ISMRM, Milan Italy, #3318, 5/13/14.
  • Dual biomarker CEST-MRI evaluates tumor pH and vascular perfusion in an orthotopic ovarian cancer model.  Chen LQ, Jones KM, Howison CM, Chambers SK, Baker AF, Pagel MD. Proc ISMRM, Milan Italy, #1145, 5/13/14.
  • Monitoring extracelluar pH, spatial heterogeneity and contrast agent uptake in lymphoma tumor models with acidoCEST MRI.  Chen LQ, Howison CM, Baker AF, Pagel MD. Proc ISMRM, Milan Italy, #3160, 5/13/14.
  • Monitoring re-cellularization of acellularized organs with iron oxide nanoparticles and T2W-MRI. Kobes JE, Georgiev GI, Lewis AV, Rilo HL, Khalpey Z, Pagel MD. Proc ISMRM, Milan Italy, #2809, 5/13/14.
  • Monitoring response to drug-loaded PLGA nanoparticles in a MiaPaCa-2 pancreatic tumor model with T2 and diffusion-weighted MRI.  Kobes JE, Daryaei I, Howison CM, Meuillet E, Pagel MD.  Proc ISMRM, Milan Italy, #1124, 5/13/14.
  • Detection of cathepsin B activity with diamagnetic Chemical Exchange Caturation Transfer (diaCEST) MRI.  Hingorani DV, Montano LA, Randtke EA, Cárdenas-Rodríguez J, Pagel MD.  ICMRBS meeting, Dallas, TX, 8/26/14.
  • Monitoring early therapeutic response by measuring extracellular pH in a tumor model with acidoCEST MRI.  Akhenblit PJ, Howison CM, Chen LQ, Malm S, Baker AF, Pagel MD.  WMIC, Seoul, Korea, 9/18/14.
  • Detection of cathepsin B activity with diamagnetic Chemical Exchange Saturation Transfer (diaCEST) MRI.  Hingorani DV, Montano LA, Randtke EA, Cárdenas-Rodríguez J, Pagel MD.  WMIC, Seoul, Korea, 9/18/14.
  • Orthotopic vs. xenograft tumor location profoundly affects the extracellular tumor microenvironment as monitored with acidoCEST MRI.  Jones KM, Chen LQ, Howison CM, Chambers SK, Baker AF, Pagel MD.  WMIC, Seoul, Korea, 9/18/14.
  • Monitoring recellularization of acellularized organs with iron oxide nanoparticles or silica nanoparticles: a comparitive study.  Kobes JE, Georgiev GI, Louis A, Rilo H, Khalpey Z, Pagel MD.  WMIC, Seoul, Korea, 9/18/14.
  • Monitoring response to drug-loaded PLGA nanoparticles in a MiaPaCa-2 pancreatic tumor model with T2 and diffusion-weighted MRI. Kobes JE, Daryaei I, Howison CM, Bontrager JG, Meuillet EM, Pagel MD.  WMIC, Seoul, Korea, 9/18/14.
  • Direct measurements of chemical exchange rates from image contrast via B1 modulation of diamagnetic on-resonance CEST MRI.  Randtke EA, Pagel MD, Cárdenas-Rodríguez J.  WMIC, Seoul, Korea, 9/18/14.

2013

  • Measuring extracellular pH within in vivo tumors using acidoCEST MRI. Chen LQ, Howison CM, Jeffery JJ, Robey I, Pagel MD. American Association of Cancer Research, 4/8/13.
  • Evaluation of a TGase-responsive PARACEST MRI contrast agent: The influence of conformations and non-covalent adducts.  Hingorani DV, Randtke EA, Pagel MD.  Proc ISMRM, Salt Lake City, UT, #1906, 4/23/13. 
  • The Hanes-Woolf Linear QUESP method provides the most accurate cetermination of fast chemical exchange rates for CEST MRI contrast agents.  Randtke EA, Chen LC, Pagel MD.  Proc ISMRM, Salt Lake City, UT, #1908, 4/23/13.
  • A New Type of Responsive MRI Contrast Agents That Modulate T2ex Relaxation: Detection of Nitric Oxide.   Daryaei I, Pagel MD.  Proc ISMRM, Salt Lake City, UT, #1910, 4/23/13. 
  • Evaluation of the concentration of lanthanide ions in ex vivo mouse tissue using BMS NMR spectroscopy.  Gonzalez SI, Hingorani DV, Pagel M. Proc ISMRM, Salt Lake City, UT, #3870, 4/24/13. 
  • Improved measurements of chemical exchange rates with linear QUEST MRI.  Randtke EA, Chen LQ, Pagel MD. WMIC, Savannah GA, 9/20/13.
  • Monitoring extracellular pH during tumor growth with acidoCEST MRI.  Chen LQ, Howison CM, Baker AF, Pagel MD. WMIC, Savannah GA, 9/20/13.
  • An enzyme-responsive PARACEST MRI contrast agent that "turns on" after catalysis.  Hingorani DV, Pagel MD.  WMIC, Savannah GA, 9/20/13.
  • Evaluating the extracellular pH of tumors in vivo using acidoCEST MRI.  Moon BF, Chen LQ, Liu P, Howison CM, Jones KM, Pagel MD. ABRCMS, Nashville TN, 11/14/13. 
  • Evaluation of the concentration of lanthanide ions in ex vivo mouse tissue using BMS NMR spectroscopy.  Gonzalez SI, Hingorani DV, Pagel M.  ABRCMS, Nashville TN, 11/14/13.

2012

  • Nanoparticles delivery of a novel akt/pdk1 inhibitor inhibits pancreatic cancer tumor growth. Moses S, Lucero-Acuna A, Jeffrey J, Guzman R, Pagel MD, Meuillet EJ., AACR, 4/2/12.
  • A linear algorithm of the reference region model for DCEMRI is fast and relaxes requirements for temporal resolution and signaltonoise ratio.  Cardenas-Rodriguez J, Howison C, Pagel MD. ISMRM, Melbourne Australia, 5/9/12.
  • A new reference agent model for DCE-MRI that exploits selective detection of two 19F MRI contrast agents.  Cardenas-Rodriguez J, Howison C, Matsunaga TO, Pagel MD. ISMRM, Melbourne Australia, 5/9/12.
  • Measuring tumor acidosis and enzyme activity with CEST MRI. Chen LQ, Hingorani D, Howison CM, Jeffery JJ, Pagel MD.  Imaging in 2020, Jackson WY, 10/1/12.
  • An enzyme-responsive PARACEST MRI contrast agent that "turns on" after catalysis.  Hingorani DV, Pagel MD.  OctoberCEST, Annapolis MD, 10/15/12.
  • Measuring extracellular pH within in vivo tumors using acidoCEST MRI.  Chen LQ, Howison CM, Jeffery JJ, Robey I, Pagel MD.  OctoberCEST, 10/15/12.

2011

  • Detection of in vivo enzyme activity with PARACEST MRI. Yoo B, Sheth VR, Howison CM, Douglas M, Pineda C, Baker AF, Pagel MD. ISMRM, Montreal QB, 5/10/11.
  • A self-calibrating PARACEST MRI contrast agent that detects esterase enzyme activity.  Li Y, Sheth VR, Liu G, Pagel MD, ISMRM, Montreal QB, 5/10/11.
  • Combining DCE-MRI vs. DW-MRI for evaluating the early response of a hypoxia-activated chemotherapy.  Cárdenas-Rodríguez J, Li Y, Galons JP, Cornnell H, Pagel MD, Baker AF. ISMRM, Montreal QB, 5/10/11.
  • Measuring in vivo tumor pHe with a PARACEST MRI contrast agent. Sheth VR, Li Y, Chen LQ, Howison CM, Pagel MD. ISMRM, Montreal QB, 5/10/11.
  • Investigation of 1H and 19F imaging biomarkers to monitor the response to a hypoxia activated anticancer drug. Cárdenas-Rodríguez J, Pagel MD.  Era of Hope DOD Breast Cancer Research Program meeting, 8/3/11.
  • Improved assessments of tumor angiogenesis using two 19F MRI contrast agents and a relative permeability model for DCE-MRI.  Cárdenas-Rodriguez J, Howison CM, Matsunaga TO, Pagel MD.  WMIC, San Diego CA, 9/8/11.
  • Improved detection of colon lesions in mouse models using dual-contrast micro-CT.  Jeffery JJ, Pagel MD, Paine-Murrieta G.  WMIC, San Diego CA, 9/8/11.

2010

  • Measuring tumor pH with MRI: a biomarker for anti-cancer drug development and personalized medicinePagel MD.  IdeaFunding 2010, Tucson, AZ, 10/28/10.
  • Measuring enzyme performance with MRI: a biomarker for anti-cancer drug development and personalized medicine. Pagel MD.  IdeaFunding 2010, Tucson, AZ, 10/28/10.
  • Measuring tumor extracellular pH with CEST MRI.  Sheth VR, Chen LQ, Li Y, Pagel MD.  Cancer Biology Retreat, University of Arizona, Oracle, AZ, 10/2/10.

2009

  • Development of spontaneously disassembling dendrimers as a platform technology for PARACEST MRI contrast agents. Li Y, Pagel MD. ISMRM, Honolulu, HI, 4/22/09.
  • Towards the development of a single PARACEST MRI contrast agent for tumor pH measurements.  Sheth VR, Liu G, Li Y, Pagel MD. ISMRM, Honolulu, HI, 4/22/09.
  • Detection of urokinase Plasminogen Activator enzyme activity with PARACEST MRI. Yoo B, Sheth VR, Sundaram AV, Ali MM, Pagel MD.  World Molecular Imaging Congress Meeting, Montreal Canada, 9/26/09.
  • Validation of pH measurements determined from a single PARACEST MRI contrast agent.  Sheth VR, Li Y, Pagel MD. World Molecular Imaging Congress Meeting, Montreal Canada, 9/26/09.
  • Detection of human malignant glioma in an experimental rat model by PARACEST MRI.  Ali MM, ASM Iskander ASM, Varma NRS, Janic B, Knight R, Pagel M, Arbab AS. World Molecular Imaging Congress Meeting, Montreal Canada, 9/26/09.

2008

  • A comparison of PARACEST DCE MRI with T1 relaxivity-based DCE MRI.  Yoo B, Liu G, Rosenblum RM, Pagel MD. Society for Molecular Imaging meeting, Providence RI, 9/9/08.
  • Diffusion kurtosis MRI for tumor assessmentsLiu G, Pagel MD.  Society for Molecular Imaging meeting, Providence RI, 9/9/08.
  • Improved assessments of breast cancer with DCE-MRI using two dendritic PARACEST agentsAli MM, Pagel MD. Society for Molecular Imaging meeting, Providence RI, 9/9/08.
  • A PARACEST MRI contrast agent that detects esterase enzymes. Li Y, Liu G, Pagel MD.  Society for Molecular Imaging meeting, Providence RI, 9/9/08.
  • A new class of PARACEST MRI contrast agents for extracellular pH measurements. Liu G, Li Y, Pagel MD. Society for Molecular Imaging meeting, Providence RI, 9/9/08.
  • Longer in vivo retention and accumulation improves detection of PARACEST MRI contrast agents.  Ali MM, Pagel MD.  ISMRM, Toronto CA, 5/7/08.
  • FISPCEST: A rapid acquisition for dynamic detection of CEST/PARACEST activity.  Shah T, Ali MM, Liu G, Pagel MD, Flask CA.  ISMRM, Toronto CA, 5/7/08.
  • An enzyme-responsive PARACEST MRI contrast agent that detects caspase-3Yoo B, Pagel MD, DOD Era of Hope meeting, 6/26/08.
  • In vivo measurements of tumor extracellular pH with a single PARACEST MRI contrast agent.  Sheth VR, Li Y, Liu G, Pagel MD. World Molecular Imaging Congress Meeting, Nice, France, 9/25/08.
  • In vivo PARACEST MRI: Overcoming challenges of temporal resolution, sensitivity, and quantificationSheth VR, Shah T, Flask CA, Liu G, Ali M, Pagel MD. World Molecular Imaging Congress Meeting, Nice, France, 9/25/08.
  • Development of a single PARACEST MRI contrast agent for tumor pH measurements.  Sheth VRLiu, G, Li Y, Pagel MD.  MRI of Cancer Workshop, ISMRM, Nice France, 9/27/08.

2007

  • Strategies to improve the temporal resolution of PARACEST MRI.  Liu G, Pagel MD. ISMRM, Berlin Germany, 5/23/07.
  • A PARACEST MRI contrast agent that detects esterase enzymes. Li Y, Liu G, Pagel MD. ISMRM, Berlin Germany, 5/23/07.
  • Towards the detection of hepatocellular carcinoma with a pH-responsive dendritic MRI contrast agent.  Ali M, Pagel MD. ISMRM, Berlin Germany, 5/23/07.
  • Improved detection of glycosaminoglycan content in cartilage using PARACEST MRI contrast agents.  Li Y, Liu G, Dong F, Pagel MD.  ISMRM, Berlin Germany, 5/23/07.
  • Longitudinal MRI evaluations of lung inflammation within cystic fibrosis mouse models.  Sheth VR, Pagel MD. ISMRM, Berlin Germany, 5/19/07.
  • Optimization of intracellular delivery of PARACEST contrast agents by combining liposomes and cell penetrating peptidesRosenblum R, Yoo B, Pagel MD. ISMRM, Berlin Germany, 5/23/07.
  • Enzyme-responsive PARACEST MRI contrast agents that assess subsets of the human degradome. Yoo B, Sheth VR, Raam MS, Pagel MD. ISMRM, Berlin Germany, 5/23/07.
  • A single PARACEST MRI contrast agent for accurate in vivo pH measurements.  Liu G, Li Y, Pagel MD. ISMRM, Berlin Germany, 5/23/07.
  • Strategies to improve the temporal resolution of PARACEST MRI.  Liu G, Pagel MD. Experimental NMR Conference, Daytona FL, 4/25/07.
  • A single PARACEST MRI contrast agent for accurate in vivo pH measurements.  Liu G, Li Y, Pagel MD. Experimental NMR Conference, Daytona FL, 4/25/07.

2006

  • A smart PARACEST MRI contrast agent for nitric oxide detection, Liu G, Pagel MD. ISMRM, Seattle WA, 5/9/06.
  • A “smart” PARACEST agent for detection of transglutaminase activity, Rosenblum R, Pagel MD. ISMRM, Seattle WA, 5/9/06.
  • New flexible solution phase and solid phase peptide synthesis methods for peptide-DOTA molecular imaging probes.  Byunghee Yoo and Marty Pagel, Fall ACS Meeting, San Francisco CA, 9/11/06.
  • A new “smart” PARACEST MRI probe that detects enzyme activityByunghee Yoo and Marty Pagel, Fall ACS Meeting, San Francisco CA, 9/11/06.
  • pH-sensitive biotinylated dendritic MRI probe to improve detection of liver tumorsMd. Ali and Marty Pagel, Fall ACS Meeting, San Francisco CA, 9/11/06.
  • A smart MRI contrast agent for nitric oxide detection, Guanshu Liu and Marty Pagel, Fall ACS Meeting, San Francisco CA, 9/11/06.
  • A “smart” PARACEST agent for detection of caspase-3 activity, Yoo B, Pagel MD. RSNA, Chicago IL, 11/27/06.
  • A novel PARACEST MRI agent for pH measurements, Liu G, Li Y, Pagel MD. RSNA, Chicago IL, 11/27/06.

2005

  • Development of new in vivo MRI contrast agents to assess cartilage glycosaminoglycan concentrations, Dong F, Dennis J, Pagel MD. The Cartilage Innovation Summit 2005, Cleveland, OH, 5/4/05.
  • Novel molecular imaging agents to detect biomarkers of metastatic breast cancer, Yoo B, Raam M, Pagel MD. Era of Hope 2005 Department of Defense Breast Cancer Research Program Meeting, Philadelphia, PA, 6/8-11/05.
  • New MRI contrast agents to improve assessments of cartilage glycosaminoglycan concentrations, Dong F, Dennis J, Pagel MD. Society for Molecular Imaging 2005 Meeting, Colgne Germany, 9/7-10/05.
  • Flexible synthesis of DOTA-peptides for molecular imaging, Yoo B, Pagel MD. Society for Molecular Imaging 2005 Meeting, Colgne Germany, 9/7-10/05.
  • Development of new in vivo MRI contrast agents to assess cartilage glycosaminoglycan concentrations, Dong F, Dennis J, Pagel MD. The Cartilage Innovation Summit 2005, Cleveland, OH, 5/4/05.
  • Novel molecular imaging agents to detect biomarkers of metastatic breast cancer, Yoo B, Raam M, Pagel MD. Era of Hope 2005 Department of Defense Breast Cancer Research Program Meeting, Philadelphia, PA, 6/8-11/05.
  • New MRI contrast agents to improve assessments of cartilage glycosaminoglycan concentrations, Dong F, Dennis J, Pagel MD. Society for Molecular Imaging 2005 Meeting, Colgne Germany, 9/7-10/05.
  • Flexible synthesis of DOTA-peptides for molecular imaging, Yoo B, Pagel MD. Society for Molecular Imaging 2005 Meeting, Colgne Germany, 9/7-10/05.
  • "Smart" PARACEST MRI agents that detect multiple enzyme biomarkers, Pagel MD, Yoo B, Liu G, Dong FRosenblum R. Imaging in 2020 Meeting, Jackson WY, 9/25-29/05.
  • Smart PARACEST MRI contrast agent for nitric oxide detection, Liu G, Pagel MD. Memphis Bioimaging Meeting, 11/4/05.

2003

  • Merits of multiple contrast agents and pixel-by-pixel analyses for detection of early changes in vascular permeabilities in murine tumor models following drug therapy and/or radiation therapy, Pagel MD, Baldwin SJ, O’Neal J, Ornberg R, Davis T, Kotyk J. ISMRM, Toronto ON, 7/11/03.